Dan-Qin Sun
Overview
Explore the profile of Dan-Qin Sun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu M, Sun D, Yang F, Zheng X, Wu N, Zhang H, et al.
Front Endocrinol (Lausanne)
. 2025 Mar;
16:1505050.
PMID: 40034234
Purpose: This study aimed to assess the relationship between regional body composition and metabolic dysfunction-associated fatty liver disease (MAFLD) in Chinese children. Methods: In this study, 1399 children aged 7-14...
2.
Zhou J, Sun D, Targher G, Byrne C, Lee B, Hamaguchi M, et al.
eGastroenterology
. 2025 Feb;
1(1):e100005.
PMID: 39944252
Background And Aim: Metabolic dysfunction-associated fatty liver disease (MAFLD) is an alternative description and classification of non-alcoholic fatty liver disease (NAFLD) that may have better utility than NAFLD in clinical...
3.
Chen W, Zhang J, Chen L, Byrne C, Targher G, Luo L, et al.
Clin Mol Hepatol
. 2024 Oct;
31(1):56-73.
PMID: 39428978
Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the...
4.
Zhang H, Targher G, Byrne C, Kim S, Wong V, Valenti L, et al.
Hepatol Int
. 2024 Jun;
18(4):1178-1201.
PMID: 38878111
Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it...
5.
Zhao J, Liu L, Cao Y, Gao X, Targher G, Byrne C, et al.
Hepatol Int
. 2024 Apr;
18(Suppl 2):834-847.
PMID: 38594474
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. In recent years, a new terminology and definition of metabolic dysfunction-associated fatty liver disease (MAFLD)...
6.
Tang L, Sun D, Song S, Yip T, Wong G, Zhu P, et al.
Liver Int
. 2024 Mar;
44(5):1129-1141.
PMID: 38426611
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N-terminal propeptide of collagen type 3 (PRO-C3) is a biomarker of advanced fibrosis...
7.
Sun D, Yuan F, Fu M, Zhong M, Zhang S, Lu Y, et al.
Mol Metab
. 2023 Nov;
79:101841.
PMID: 38036169
Objective: Activation of farnesoid X receptor (FXR), a bile acid nuclear receptor, may be implicated in the pathophysiology of diabetic nephropathy. We explored a possible role for FXR activation in...
8.
Sun D, Targher G, Byrne C, Wheeler D, Wong V, Fan J, et al.
Hepatobiliary Surg Nutr
. 2023 Jun;
12(3):386-403.
PMID: 37351121
Background: With the rising global prevalence of fatty liver disease related to metabolic dysfunction, the association of this common liver condition with chronic kidney disease (CKD) has become increasingly evident....
9.
Feng G, Zhang X, Zhang L, Liu W, Geng S, Yuan H, et al.
Liver Int
. 2023 Mar;
43(6):1234-1246.
PMID: 36924436
Background & Aims: There is an unmet clinical need for non-invasive tests to diagnose non-alcoholic fatty liver disease (NAFLD) and individual fibrosis stages. We aimed to test whether urine protein...
10.
Liu A, Xu C, Liu Y, Sun D, Jiang L, Tang L, et al.
Aliment Pharmacol Ther
. 2023 Jan;
57(8):872-885.
PMID: 36670060
Background: Dysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD). Aim: To determine whether circulating BA levels accurately stage liver...